IMVARIA Inc., a health tech company focused on developing AI-driven digital biomarker solutions, announced today that its AI-powered diagnostic platform, Bronchosolve, successfully met the primary endpoints in the pivotal VIRTUAL-BRONCH Study. The study evaluated Bronchosolve’s ability to non-invasively assess suspicious pulmonary nodules, a critical step in early lung cancer detection. Results showed a significant improvement in diagnostic accuracy compared to standard clinical practices, offering a promising alternative to more invasive procedures like traditional bronchoscopy. Bronchosolve leverages advanced artificial intelligence to analyze data from routine imaging and patient health information, identifying patterns associated with lung cancer with high precision. By enabling earlier and more accurate diagnosis without the need for invasive interventions, the platform has the potential to transform lung cancer screening and reduce patient risk and healthcare costs. The findings from the VIRTUAL-BRONCH Study will be presented at a major scientific conference in 2026. IMVARIA emphasized that the positive outcomes reinforce the platform’s potential to become a key tool in the early detection of lung cancer, a leading cause of cancer-related deaths worldwide. The company is now advancing its regulatory and commercialization plans, with the goal of bringing Bronchosolve to clinical use in the near future.